Buy or sell Rgenix stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Rgenix Stock

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating first-in-class therapeutics.

Founded

2010

Headquarters

New York NY, US

Total Funding

$83.5M

About Rgenix Stock

Rgenix is a a discovery platform, revolutionizing the treatment of cancer by generating first-in-class therapeutics that target key nodes in cancer progression. Its proprietary discovery platform is based on innovations in cancer biology that enable the identification and validation of novel post-transcriptionally regulated targets. Rgenix’s productive approach has yielded multiple novel targets to date across several cancer types for which the company is developing drugs, and its scientific approach has led to the discovery of novel therapeutic targets and first-in-class drugs for several cancer sub-types, including melanoma, colorectal cancer and triple-negative breast cancer, among others. Its aim is to discover and develop safe, effective, and commercially viable therapies that will transform the lives of cancer patients by treating metastatic disease. Rgenix was developed by founding scientists Dr. Sohail Tavazoie and Dr. Saeed Tavazoie. It was launched in 2010.

Funding History

September 2013$2.5M
August 2015$8.0M
June 2016$33.0M
October 2018$40.0M

Management

CFO

David Darst

Co-Founder

Masoud Tavazoie

Co-Founder

Shahram Seyedin-Noor

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Rgenix or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo